Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation

Inflammatory Bowel Diseases

Volumn 11, Issue 11, 2005, Pages 977-985

  Hoentjen, Frank ^a,b   Welling, Gjalt W ^c   Harmsen, Hermie J M ^c   Zhang, Xiaoyin ^a   Snart, Jennifer ^d   Tannock, Gerald W ^d   Lien, Kelvin ^d   Churchill, Thomas A ^f   Lupicki, Maryla ^e   Dieleman, Levinus A ^a,e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Surgical Medical Research Institute   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f Zeidler Ledcor Centre ^*

Author keywords

Colitis; Commensal intestinal bacteria; Cytokines; HLA B27 transgenic rats; Immunomodulation; Prebiotics

Indexed keywords

FATTY ACID; FRUCTOSE; HLA B27 ANTIGEN; INULIN; INULIN PLUS OLIGOFRUCTOSE; PREBIOTIC AGENT; SYNERGY 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BIFIDOBACTERIUM; COLITIS; COLON; CONTROLLED STUDY; DRUG MECHANISM; ENTERITIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS; LIPID COMPOSITION; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; SCORING SYSTEM; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CECUM; COLITIS; COLON; CYTOKINES; DNA, BACTERIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HLA-B27 ANTIGEN; IN SITU HYBRIDIZATION, FLUORESCENCE; INFLAMMATION; POLYMERASE CHAIN REACTION; PROBIOTICS; RATS; RATS, INBRED F344; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 27644439119     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000183421.02316.d5     Document Type: Article

References (52)

1. Sartor RB. Innate immunity in the pathogenesis and therapy of IBD. J Gastroenterol. 2003;38(Suppl 15):43-47.
2. Sartor RB, Hoentjen F. Proinflammatory cytokines and signaling pathways in intestinal innate immune cells. In: Mestecky J, McGhee JR, Strober W, eds. Mucosal Immunology. 3rd ed, 2005:681-702.
3. Sartor RB. Animal models of intestinal inflammation. Kirsner's Inflammatory Bowel Diseases. 6th ed: Elsevier, 2004:120-137.
4. Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63;1099-1112.
5. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359-2364.
6. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun. 2001;69:2277-2285.
7. Rath HC, Ikeda JS, Linde HJ, et al. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology. 1999;116:310-319.
8. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun. 1999;67:2969-2974.
9. Reid G, Sanders ME, Gaskins HR, et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol. 2003;37:105-118.
10. Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299v in the treatment and prevention of spontaneous colitis in interleukin-10- deficient mice. Inflamm Bowel Dis. 2002;8:71-80.
11. Dieleman LA, Goerres MS, Arends A, et al. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut. 2003;52:370-376.
12. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. Am J Gastroenterol. 2005;100:1539-1546.
13. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
14. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401-1412.
15. Kleessen B, Hartmann L, Blaut M. Oligofructose and long-chain inulin: influence on the gut microbial ecology of rats associated with a human faecal flora. Br J Nutr. 2001;86:291-300.
16. Roberfroid MB. Prebiotics and synbiotics: concepts and nutritional properties. Br J Nutr. 1998;80:S197-S202.
17. Videla S, Vilaseca J, Antolin M, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol. 2001;96:1486-1493.
18. Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J Nutr. 2003;133:21-27.
19. Dieleman LA, Hoentjen F, Qian BF, et al. Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. Clin Exp Immunol. 2004;136:30-39.
20. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest. 1996;98:945-953.
21. Cominelli F, Nast CC, Clark BD, et al. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest. 1990;86:972-980.
22. Tannock GW, Munro K, Harmsen HJ, et al. Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol. 2000;66:2578-2588.
23. Knarreborg A, Simon MA, Engberg RM, et al. Effects of dietary fat source and subtherapeutic levels of antibiotic on the bacterial community in the ileum of broiler chickens at various ages. Appl Environ Microbiol. 2002;68:5918-5924.
24. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol. 1990;215:403-410.
25. Hoentjen F, Harmsen HJ, Braat H, et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut. 2003;52:1721-1727.
26. Franks AH, Harmsen HJ, Raangs GC, et al. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol. 1998;64:3336-3345.
27. Manz WR, Amann R, Ludwig W, et al. Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga-flavobacter-bacteroides in the natural environment. Microbiol. 1996;142:1097-1106.
28. Langendijk PS, Schut F, Jansen GJ, et al. Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples. Appl Environ Microbiol. 1995;61:3069-3075.
29. Harmsen HJM, Elfferich P, Schut F, et al. A 16S rRNA-targeted probe for detection of lactobacilli and enterococci in fecal samples by fluorescent in situ hybridization. Microbiol Ecol in Health and Dis. 1999;11:3-12.
30. Harmsen HJ, Raangs GC, He T, et al. Extensive set of 16S rRNA-based probes for detection of bacteria in human feces. Appl Environ Microbiol. 2002;68:2982-2990.
31. Jansen GJ, Wildeboer-Veloo AC, Tonk RH, et al. Development and validation of an automated, microscopy-based method for enumeration of groups of intestinal bacteria. J Microbiol Methods. 1999;37:215-221.
32. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-1633.
33. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.
34. Schultz M, Munro K, Tannock GW, et al. Effects of feeding a probiotic preparation (SIM) containing inulin on the severity of colitis and on the composition of the intestinal microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immunol. 2004;11:581-587.
35. Holma R, Juvonen P, Asmawi MZ, et al. Galacto-oligosaccharides stimulate the growth of bifidobacteria but fail to attenuate inflammation in experimental colitis in rats. Scand J Gastroenterol. 2002;37:1042-1047.
36. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifido-bacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242-249.
37. Welters CF, Heineman E, Thunnissen FB, et al. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum. 2002;45:621-627.
38. Kanauchi O, Suga T, Tochihara M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol. 2002;37(Suppl 14):67-72.
39. Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med. 2003;12:701-704.
40. Baharav E, Mor F, Halpern M, et al. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr. 2004;134:1964-1969.
41. Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritisin DBA/1 mice. Life Sci. 1998;63:635-644.
42. Langlands SJ, Hopkins MJ, Coleman N, et al. Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel. Gut. 2004;53:1610-1616.
43. Shiba T, Aiba Y, Ishikawa H, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol. 2003;47:371-378.
44. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22:56-63.
45. Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol. 2003;69:1920-1927.
46. Bamba T, Kanauchi O, Andoh A, et al. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol. 2002;17:818-824.
47. Fukuda M, Kanauchi O, Araki Y, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med. 2002;9:65-70.
48. Roller M, Rechkemmer G, Watzl B. Prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis modulates intestinal immune functions in rats. J Nutr. 2004;134:153-156.
49. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002;109:119-121.
50. Powrie F, Carlino J, Leach MW. A critical role for transforming-growth factor-beta but not interleukin-4 in the suppression of T helper 1-mediated colitis by CD45RB(low) CD4 T cells. J Exp Med. 1996;183:2669-2674.
51. Kitani A, Fuss IJ, Nakamura K, et al. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J Exp Med. 2000;192:41-52.
52. Schiffrin EJ, Yousfi ME, Faure M, et al. Casein-based diet containing TGF-(beta) controls the inflammatory reaction in the HLA-B27 transgenic rat model. JPEN J Parenter Enteral Nutr. 2005;29:S141-S150.